依那普利联合阿托伐他汀治疗糖尿病肾病的临床分析

Clinical analysis of enalapril combined with atorvastatin in diabetic nephropathy

目的探讨依那普利与阿托伐他汀联合用于糖尿病肾病治疗的临床效果。方法选取2014年8月～2016年8月杭州电子科技大学校医院收治的108例糖尿病肾病患者,随机分为观察组与对照组,每组各54例。对照组在一般糖尿病治疗基础上加用依那普利治疗,观察组再对照组基础上加用阿托伐他汀治疗,观察并比较2组患者治疗后空腹血糖（FPG）、餐后2 h血葡萄糖（2h PG）、糖化血红蛋白（Hb Alc）、收缩压（SBP）,舒张压（DBP）、尿白蛋白排泄率（UAER）,血肌酐（SCr）、内生肌酐清除率（Ccr）的变化情况。结果治疗后,对照组和观察组患者糖尿病指标FPG、2 h PG及Hb Alc比治疗前均有显著性降低,差异有统计学意义（P〈0.05）,但治疗后2组比较均差异无统计学意义。对照组和观察组患者糖尿病肾病指标SBP、DBP、UAER、Scr、Ccr比治疗前均显著减低,差异有统计学意义（P〈0.05）,且治疗后观察组UAER、Scr、Ccr显著低于对照组,差异有统计学意义（P〈0.05）。结论依那普利与阿托伐他汀联合用于糖尿病肾病的治疗,能够在良好控制血糖的基础上有效延缓糖尿病肾病病程进展,保护肾功能。

Objective To investigate the clinical effects of enalapril combined with atorvastatin in the treatment of diabetic nephropathy.Methods108 patients with diabetic nephropathy from August 2014 to August 2016 were selected and randomly divided into the observation group and the control group,54 cases in each group.The control group were treated with enalapril based on the conventional diabetes treatment,and the observation group were treated with atorvastatin based on the control group,the changes of FPG,2 h PG,Hb Alc,SBP,DBP,UAER,SCr and Ccr were observed and compared between the two groups.Results After treatment,the control group and the observation group patients with diabetes indicators FPG,2 h PG and Hb Alc in the control group,were significantly lower than before treatment,the difference was statistically significant（P〈0.05）,but there was no statistically significant difference between the two groups after treatment.The control group and the observation group patients with diabetic nephropathy,SBP,DBP,UAER,Scr,Ccr were significantly lower than before treatment,the difference was statistically significant（P〈0.05）,and after treatment,UAER,Scr and Ccr in the observation group were significantly lower than those in the control group,the difference was statistically significant（P〈0.05）.Conclusion Enalapril combined with atorvastatin can effectively delay the progression of the disease,protect renal function based on good control of blood glucose in the treatment of diabetic nephropathy.